5. Progressive supranuclear palsy Clinical trials / Disease details

Clinical trials : 89 / Drugs : 107 - (DrugBank : 40) / Drug target genes : 65 - Drug target pathways : 108

2 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2006-006166-42-DE (EUCTR)	17/07/2007	02/01/2007	Exelon bei dementiellem Syndrom bei Patienten mit Progressiver Supranukleärer Parese -offene, prospektive Phase II-Studie -	Exelon bei dementiellem Syndrom bei Patienten mit Progressiver Supranukleärer Parese -offene, prospektive Phase II-Studie -	Progressive supranuclear palsy (PSP) is a neurodegenerative disorder with hardly any therapeutical option to ameliorate the course of the disease. Results of first trials with physostigmine and donepezil did not point out a definite benefit. In contrast, first clinical observations concerning an effect with rivastigmine in PSP with dementia were promising. This may be due to the fact, that rivastigmine excerts a double action inhibiting both the acetylcholin- and the buturylcholinesterase.	Trade Name: Exelon 1,5 mg Hartkapseln INN or Proposed INN: RIVASTIGMINE Trade Name: Exelon 3,0 mg Hartkapseln INN or Proposed INN: RIVASTIGMINE Trade Name: Exelon 6,0 mg Hartkapseln INN or Proposed INN: RIVASTIGMINE	University of Tuebingen	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes		Phase 2	Germany
2	NCT00139373 (ClinicalTrials.gov)	May 2005	30/8/2005	Study of the Distractibility Syndrome in Patients With Progressive Supranuclear Palsy	Study of the Distractibility Syndrome in Patients With Progressive Supranuclear Palsy	Supranuclear Palsy, Progressive	Drug: donepezil	Groupe Hospitalier Pitie-Salpetriere	Institut National de la Santé Et de la Recherche Médicale, France	Recruiting	30 Years	80 Years	Both	16	Phase 2	France